Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
$1.61
-$0.04(-6.64%)
At close: 4:00 PM EST
$1.61
-$0.04(-6.64%)
Day’s Range― - ―
52-Week Range$0.37 - $2.09
Previous CloseN/A
Volume522.43K
Average Volume (3M)2.15M
Market Cap
$382.34M
Enterprise Value$347.65M
Total Cash (Recent Filing)$40.49M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding230,327,530
10 Day Avg. Volume1,292,978
30 Day Avg. Volume2,150,723
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.28
Price to Sales (P/S)10.59
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue32.14
Enterprise Value/Gross Profit32.85
Enterprise Value/Ebitda-7.62
Forecast
1Y Price Target
$4.60Price Target Upside185.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$9.90M
Bulls Say, Bears Say
Bulls Say
Clinical Data And ResultsOpRegen data show unheard of reversal with significant improvements in vision and overall patient benefit.
Program CollaborationThe $5 million milestone payment from Roche indicates tangible progress in the OpRegen program.
Research And DevelopmentLineage announced a research collaboration with William Demant Invest to help fund the advancement of ReSonance through preclinical studies for hearing loss.
Bears Say
Financial PerformanceLineage reported a wider than expected loss due to warrant liability accounting, impacting financial results.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $382.34M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Mar 05, 2026 which is in 91 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.026 by -$0.104.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 230,327,530 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.026. Following the earnings report the stock price went up 1.734%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.60 (185.71% Upside)
$4.60 (185.71% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
209.85%
12-Months-Change
Fundamentals
Return on Equity
-153.37%
Trailing 12-Months
Asset Growth
-7.20%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Therap (LCTX) is a biotechnology company focused on developing and commercializing innovative therapies for patients with degenerative diseases. The company primarily operates in the regenerative medicine sector, leveraging its expertise in stem cell technology to create advanced therapeutic solutions. Lineage Therap's core products are stem cell-derived therapies aimed at treating conditions such as age-related macular degeneration and spinal cord injuries, striving to restore lost function and improve quality of life for patients.
LCTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Lineage has made significant progress with its OpRegen program and secured important partnerships, financial challenges persist with a decrease in revenue and a significant net loss. The advancements in clinical trials and partnerships offer promising long-term potential, but financial metrics present short-term challenges.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$4.60
▲(185.71% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
58.18% Insiders
4.97% Mutual Funds
25.55% Other Institutional Investors
7.91% Public Companies and
Individual Investors